While Mike is best known for leading the team that discovered Viagra at Pfizer UK, his extensive career includes serving as Chairman and Chief Scientific Officer for several highly successful drug development companies. With a deep understanding of the pharmaceutical landscape, he has developed particular expertise in the strategic planning of clinical trial studies, ensuring they are designed to meet regulatory requirements and scientific standards.

His experience extends to navigating complex regulatory environments in the US, UK, and Asia, where he has built strong relationships with key stakeholders. Additionally, Mike is skilled in identifying and developing new intellectual property, contributing to innovation and growth within the industry. His multifaceted experience makes him a valuable asset in the field of drug development.

After 23 years in investment banking, primarily based in the bustling financial hub of New York City, Jonathan took a bold leap in 2009 by founding The Sarum Oncology Fund. His goal was to capitalise on the significant advancements and transformative changes occurring in the oncology sector, which he recognised as a burgeoning field with immense potential. Following the successful divestment of the portfolio, which involved strategic decision-making and a keen understanding of market dynamics, he transitioned to become the CEO of Morvus Technology.

Under his leadership, the company has developed a diverse portfolio of innovative assets, including MTL-004, a promising therapeutic candidate. Notably, all of these assets have either been out-licensed to other organisations or spun out into independent ventures, showcasing Jonathan’s commitment to fostering growth and innovation in the healthcare industry.

Mike obtained his Bachelor of Science (BSc), Doctor of Philosophy (PhD), Diploma of Imperial College (DIC), and the Associate of the Royal College of Science (ARCS) in Life Sciences from Imperial College London, where he was honoured with a Scholarship in Life Sciences, an Exhibition in Science, and the Governors’ Graduation Prize. His PhD was performed under sponsorship of Tenneco Corporation and a Spencer Scholarship supported collaboration with US academics.

After a 20 year corporate career with Unilever and Bristol-Myers Squibb, Mike became a co-founder and director of several innovative life-science businesses. He focuses on critical areas such as oncology, paediatric medicines, orphan drugs, and diagnostics, addressing pressing medical needs and improving patient outcomes across diverse populations.

Glen graduated from the Royal Free Hospital School of Medicine, London, and after spending 5 years in the British National Health Service, joined the Pharmaceutical Industry in 1997.

Glen gained Industry drug development experience in late clinical development with AstraZeneca where he developed a number of new drugs. He was also the AZ representative on the CRUK radiation combinations alliance which brought together a number of universities to aid research being conducted by CRUK and the Royal Marsden.

Since 2002 he has been involved in translational medicine and has been accountable for the early development of anti-cancer compounds, from lead optimisation to clinical proof of concept in both solid and haematological malignancies i.e. small and large molecules, cytotoxic chemotherapy, anti- sense oligonucleotides and therapeutic vaccines.

Glen is the honorary Professor of Translational Medicine in the Department of Oncology and Metabolism at the University of Sheffield, where his academic interest is not only in oncology, but in methods to maintain health into old age. Glen works with Academia, Medical Charities, Biotech and Small Pharma companies to move new treatments into the clinic and to proof of concept.

Judith is a highly accomplished Chartered Governance Professional with extensive experience in the biotech sector, having dedicated her career to this field since 1994. Over the years, she has successfully established several companies focused on developing innovative treatments for cancer and neurological disorders, showcasing her commitment to advancing healthcare. Notably, Judith was one of the founding members of Morvus, a company renowned for its groundbreaking contributions to drug development.

In her role as finance director, she not only manages financial strategies but also provides crucial intellectual property support for Gordian, ensuring that the company’s innovations are protected and effectively leveraged in the competitive biotech landscape. Her diverse skill set and leadership have made a significant impact on the industry.

Michael co-founded RAB Capital plc in 1999 and is Executive Chairman. 
  
Michael is Chairman and/or Director of a number of UK/Irish Companies.  He was a founding member of the Hedge Fund Working Group which evolved into the Hedge Fund Standards Board. Michael is President of the Blackwater Valley Opera Board and Founding Partner of the ARK Brunel Academy.